{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:18:36Z","timestamp":1758050316062,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bulcan.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T19:15:16Z","timestamp":1665256516000},"page":"1144-1153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Naus\u00e9es-vomissements induits par les traitements anticanc\u00e9reux (NVITAC) en onco-h\u00e9matologie p\u00e9diatrique\u00a0: recommandations 2022\u00a0du Comit\u00e9 soins de support de la SFCE"],"prefix":"10.1016","volume":"109","author":[{"given":"Sandrine","family":"Thouvenin-Doulet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Mouffak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude Marie","family":"Cardine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u00efna","family":"Letort-Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Wiart-Monger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Lervat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyne","family":"Poir\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2022.08.003_bib0155","first-page":"87","article-title":"ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients","volume":"27","author":"Razvi","year":"2019","journal-title":"Support Care Cancer Off"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0160","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bulcan.2019.02.002","article-title":"Naus\u00e9es-vomissements induits par les traitements anti-canc\u00e9reux (NVITAC)\u00a0: quelle prise en charge en 2018\u00a0? Mise \u00e0 jour du r\u00e9f\u00e9rentiel AFSOS","volume":"106","author":"Jovenin","year":"2019","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0165","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/pbc.24508","article-title":"Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients","volume":"60","author":"Dupuis","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0170","first-page":"64","article-title":"Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update","author":"Patel","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0175","first-page":"323","article-title":"2016\u00a0updated MASCC\/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children","volume":"25","author":"Dupuis","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0180","doi-asserted-by":"crossref","first-page":"839e4","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0185","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/pbc.25955","article-title":"Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer","volume":"63","author":"Flank","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0190","doi-asserted-by":"crossref","first-page":"e27646","DOI":"10.1002\/pbc.27646","article-title":"Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline","volume":"66","author":"Paw Cho Sing","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0195","first-page":"271","article-title":"2016\u00a0Updated MASCC\/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents","volume":"25","author":"Jordan","year":"2017","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2022.08.003_bib0200","doi-asserted-by":"crossref","first-page":"e27584","DOI":"10.1002\/pbc.27584","article-title":"Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy","volume":"66","author":"Dupuis","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0205","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1213\/ANE.0000000000003850","article-title":"Clinical use of the pictorial baxter retching faces scale for the measurement of postoperative nausea in children","volume":"128","author":"Watcha","year":"2019","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0210","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1592\/phco.26.9.1221","article-title":"Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents","volume":"26","author":"Dupuis","year":"2006","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0215","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40264-016-0418-9","article-title":"The safety of metoclopramide in children: a systematic review and meta-analysis","volume":"39","author":"Lau Moon Lin","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0220","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.bulcan.2020.03.015","article-title":"Pr\u00e9vention et traitement des naus\u00e9es et vomissements induits par les traitements anticanc\u00e9reux (NVITAC) en h\u00e9mato-oncologie p\u00e9diatrique\u00a0: mise \u00e0 jour","volume":"107","author":"Delmotte","year":"2020","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0225","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(15)00520-3","article-title":"Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study","volume":"17","author":"Kov\u00e1cs","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0230","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MPH.0000000000001357","article-title":"Palonosetron is a better choice compared with ondansetron for the prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a resource-limited pediatric oncology center: results from a randomized control trial","volume":"41","author":"Chaudhary","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0235","first-page":"3229","article-title":"Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Bakhshi","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0240","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3\u00a0trial","volume":"16","author":"Kang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0245","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12325-018-0862-2","article-title":"Efficacy, tolerability and pharmacokinetic impact of aprepitant in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy: a randomized controlled trial","volume":"36","author":"Xiong","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0250","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/bcp.13322","article-title":"Aprepitant and fosaprepitant drug interactions: a systematic review","volume":"83","author":"Patel","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0255","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1093\/annonc\/mdq149","article-title":"Aprepitant: drug-drug interactions in perspective","volume":"21","author":"Aapro","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0260","doi-asserted-by":"crossref","first-page":"e28716","DOI":"10.1002\/pbc.28716","article-title":"Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: a systematic review","volume":"67","author":"Patel","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0265","first-page":"CD007786","article-title":"Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood","volume":"2","author":"Phillips","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0270","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1097\/MPH.0000000000001186","article-title":"Safety of dexamethasone for nausea and vomiting prophylaxis in children receiving hematopoietic stem cell transplantation","volume":"40","author":"Paw Cho Sing","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0275","unstructured":"Manuel de soins palliatifs. n.d."},{"key":"10.1016\/j.bulcan.2022.08.003_bib0280","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/pbc.25063","article-title":"Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients","volume":"61","author":"Dupuis","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0285","doi-asserted-by":"crossref","first-page":"e28532","DOI":"10.1002\/pbc.28532","article-title":"Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: an open-label, randomized phase 3\u00a0trial","volume":"67","author":"Radhakrishnan","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0290","article-title":"Efficacy of olanzapine for high and moderate emetogenic chemotherapy in children","volume":"7","author":"Lee","year":"2020","journal-title":"Child Basel Switz"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0295","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40264-014-0219-y","article-title":"The safety of olanzapine in young children: a systematic review and meta-analysis","volume":"37","author":"Flank","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.bulcan.2022.08.003_bib0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/1043454216688638","article-title":"Integrative therapeutic approaches for the management and control of nausea in children undergoing cancer treatment: a systematic review of literature","volume":"34","author":"Momani","year":"2017","journal-title":"J Pediatr Oncol Nurs"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:36:03Z","timestamp":1757792163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122003381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0007455122003381"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.08.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naus\u00e9es-vomissements induits par les traitements anticanc\u00e9reux (NVITAC) en onco-h\u00e9matologie p\u00e9diatrique\u00a0: recommandations 2022\u00a0du Comit\u00e9 soins de support de la SFCE","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}